Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Kinnon Leaves ZyGem to Helm Transgenomic

Premium

Transgenomic said this week that Paul Kinnon has been named president, CEO, and a director of the company, replacing Craig Tuttle.

Kinnon joins Transgenomic from New Zealand-based ZyGem, where he served as president and CEO. Kinnon joined ZyGem in 2007 from Invitrogen, now part of Life Technologies, where he held the positions of vice president of global strategic alliances and vice president and general manager of the applied markets business unit. Prior to that, Kinnon held business, sales, and marketing roles at Guava Technologies (now part of Millipore), Cellomics (now part of Thermo Fisher Scientific), and other life science companies.

Tuttle served as president and CEO of Transgenomic since July 2006. He was previously the president and COO of Duke Scientific, a specialty particle technology company, and before that he was the president and CEO of Applied Biotech, a point-of-care rapid diagnostics manufacturer in the Apogent Technologies group.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.